Managing Adverse Effects in Patients with HER2+ Breast Cancer

Opinion
Video

Harold J. Burstein, MD, PhD, discusses the management of adverse events in patients with HER2+ breast cancer, and the Oncology Brothers provide closing thoughts on the entire discussion.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
ProSense® is a minimally invasive treatment option that destroys tumors by freezing them, utilizing liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction.

ProSense® Cryoablation Satisfies Patients With Breast Cancer vs Alternatives

Tim Cortese
September 9th 2025
Article

THERMAC trial results revealed that the ProSense® cryoablation system showed no complications, and the highest complete ablation rate in breast cancer.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Chemotherapy Confers No Survival Benefit in Older Breast Cancer Population

Roman Fabbricatore
August 30th 2025
Article

Adjuvant chemotherapy with hormonotherapy in women at least 70 years of age with GGI-high risk HER2-negative breast cancer led to more AEs vs hormonotherapy alone.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Abemaciclib/Endocrine Therapy Improves OS in HR+/HER2– Early Breast Cancer

Ariana Pelosci
August 28th 2025
Article

Results from the monarchE study showed a statistically significant OS improvement with abemaciclib plus ET for patients with HR+/HER2– early breast cancer.

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches

Ariana Pelosci
August 14th 2025
Article

Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.